SEEK yields 2000000.00% · ABBV yields 3.06%● Live data
📍 SEEK pulled ahead of the other in Year 1
Combined, SEEK + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SEEK + ABBV for your $10,000?
TheDirectory.com, Inc. operates as an online local search and directory company in the United States. The company owns and operates a network of online local business directories and city guides, which provide business listings, directory information, and user generated reviews to consumers, who are searching online for services from local businesses through its business search engine, TheDirectory.com. It also operates various vertically targeted directories, such as Podiatrist.net, Chiropractor.net, 123HomeRepair.com, and DentistAppointments.com; and a network of Hello branded city guides, such as HelloNewYorkCity.com, HelloChicago.com, HelloMiami.com, and other guides. In addition, the company provides a suite of online marketing and branding solutions comprising search engine marketing, display advertising, Web presence, and online media and social networking products, as well as designs, develops, and deploys custom-built search engine optimized business Websites. It primarily serves small-and medium-sized businesses, advertisers focused on the local market, agencies, and resellers. The company was formerly known as Elysium Internet, Inc. and changed its name to TheDirectory.com, Inc. in May 2011. The company is based in Tampa, Florida. TheDirectory.com, Inc. is a subsidiary of FTS Group, Inc.
Full SEEK Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.